Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 May 2019
Price : $35 *
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms THE RAGTIME STUDY
- 02 May 2019 Status changed from recruiting to active, no longer recruiting.
- 02 May 2019 Planned End Date changed from 1 Mar 2020 to 30 Apr 2020.
- 02 May 2019 Planned primary completion date changed from 1 Mar 2020 to 30 Apr 2020.